• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Nicotine Patch for Cannabis Withdrawal?

Nicotine Patch for Cannabis Withdrawal?

July 3, 2021
John O’Neal, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
John O’Neal, MD. Dr. O’Neal has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Gilbert DG et al, Psychopharmacology (Berl) 2020;237(5):1507–1519

As more and more states legalize marijuana and the prevalence of cannabis use increases, more people will be experiencing cannabis withdrawal symptoms, which are difficult to treat. The authors of this study hypothesized that the degree of negative affect experienced in cannabis withdrawal would be mitigated by nicotine. They designed a randomized, blinded, placebo-controlled trial to test the hypothesis.

Investigators recruited 101 people with moderate cannabis use disorder between the ages of 18 and 35. Participants were paid to stop using cannabis for 2 weeks (abstinence verified by urine tetrahydrocannabinol [THC] levels). They were then split into two groups, with one group receiving a 7 mg nicotine patch (n = 51) and the other receiving a placebo patch (n = 50). Physical symptoms of cannabis withdrawal (such as restlessness, sleep difficulty, decreased appetite or weight loss, abdominal discomfort or nausea, tremor, or headache) and negative affect were measured every other day for 15 days using the Profile of Mood States scale (POMS).

The results showed that the nicotine patch was more effective than placebo in reducing negative affect associated with cannabis withdrawal after 7 days (Cohen’s d = 0.2). Perhaps most interestingly, the results applied to all patients, whether they were tobacco users or not. Disappointingly, nicotine patches did not reduce overall withdrawal symptoms, and in fact increased nausea, probably an effect of the nicotine. The authors note that use of a higher-strength patch might have improved the results.

CATR’s Take
Nicotine can attenuate symptoms of negative affect during cannabis withdrawal, but not primary withdrawal symptoms. The study didn’t evaluate whether nicotine helps maintain cannabis abstinence. As a clinician, you can try this fairly harmless approach for cannabis-addicted patients who already use nicotine, but don’t expect miracles.
Addiction Treatment
KEYWORDS cannabis nicotine withdrawal
    John O’Neal, MD.

    More from this author
    www.thecarlatreport.com
    Issue Date: July 3, 2021
    SUBSCRIBE NOW
    Table Of Contents
    Does CBT Enhance Pharmacotherapy for Addiction?
    Starting Buprenorphine: Is Timing Everything?
    Cannabidiol for Crack-Cocaine Craving: Negative Findings
    Nicotine Patch for Cannabis Withdrawal?
    Breastfeeding and Addiction
    The Pregnant Patient With Substance Use Disorder
    Naloxone Prescribing
    A New High-Dose Naloxone: Life Saver or Punishment?
    CME Post-Test - Addiction in Pregnancy, CATR, July/August 2021
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.